Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Chloroquine and Hydroxychloroquine (2020)

Government Record · U.S. Food and Drug Administration · June 15, 2020

U.S. Food, 2020-06-15: FDA press announcement revoking the emergency use authorisation for chloroquine and hydroxychloroquine in COVID-19 – the regulatory endpoint of the hydroxychloroquine episode that the source's comparison invokes.

Today, the U.S. Food and Drug Administration (FDA) revoked the emergency use authorization (EUA) that allowed for chloroquine phosphate and hydroxychloroquine sulfate donated to the Strategic National Stockpile to be used to treat certain hospitalized

U.S. Food, 2020-06-15: FDA press announcement revoking the emergency use authorisation for chloroquine and hydroxychloroquine in COVID-19 – the regulatory endpoint of the hydroxychloroquine episode that the source's comparison invokes. C13 FDA 2020. Study type: federal agency press announcement. Country: USA. Records what the agency did about hydroxychloroquine (EUA revoked), which is the 'other side' of the comparison the source draws; it says nothing about methylene blue. Recorded neutrally: the revocation addressed the COVID-19 EUA only, and hydroxychloroquine remains an approved drug for malaria, lupus and rheumatoid arthritis. Confidence HIGH: page opened and read; excerpt left blank because the row records the action, not a quotation. Study type: regulatory record.